NEW YORK (CNNMoney.com) -- Johnson & Johnson hasn't exactly been what you would call a good corporate citizen lately. But investors don't seem to mind.
Shares of the healthcare giant are currently trading just 6% off their 52-week high. They are actually slightly higher now than they were about five months ago when the company's recall problems first came to light.
J&J has been criticized in recent months for how it handled the recall of many of its popular over-the-counter of drugs, particularly a so-called "phantom recall" of Motrin last year.
E-mails obtained by Congress show that J&J's McNeil unit had a subcontractor buy up Motrin from drug stores without informing customers that there might have been a problem with the product.
Chief executive officer Bill Weldon testified in front of a House panel Thursday to explain the firm's actions and conceded that the company "let the public down."
It's really something that J&J has not been punished by Wall Street. Other "scandal" companies of this year have gotten crushed by investors -- especially when their leaders have had to subject themselves to a Congressional dog-and-pony show.
Now to be fair, there is probably one very compelling reason why the J&J recall woes have not led to a massive sell-off in the stock. When I last wrote about J&J in early May, several fund managers and analysts noted that they thought investors and consumers were willing to overlook J&J's problems because there were no reports of consumers getting sick from the recalled products.
And that still appears to be true. So in one major respect, J&J can't really be fairly compared to BP and Massey, where people died as a result of accidents.
J&J defenders also pointed out that the company has historically done such a great job of crisis management. The example of J&J's response to the Tylenol cyanide scare in 1982 was cited more than once.
But that was a different management team handling the company's response. Why should the current J&J regime still enjoy the goodwill that was generated nearly three decades ago?
My colleague Parija Kavilanz has done a ton of investigative reporting about the recall and has uncovered some troubling patterns.
As callous as it may sound, they are looking at the dollars and cents and are coming to the conclusion that the recalls will have only a minimal impact on the company's bottom line.
Tylenol, Motrin and other consumer products part of the McNeil division are just a small part of this health care conglomerate, which also has sizeable pharmaceutical, biotech and medical equipment divisions.
"Of course you don't like to see negative news like this. But at the same time it helps to have a lot of other products to make up for the ones that are struggling," said Tom Forester, manager of the Forester Value fund in Libertyville, Ill., which owns a position in J&J. "The beauty of J&J is that it's so large and is so diversified," he said.
Forester added that J&J, trading at about 12 times 2011 earnings estimates, isn't a sexy growth stock. Many of its investors are buying it for the long-term and not trading it like a high-tech momentum stock.
Kent Gasaway, a portfolio manager with the Buffalo Funds in Kansas City, which also owns J&J, agreed.
Gasaway said that his firm invests in companies with at least a three-to-five year horizon, and that he's not spending too much time thinking about whether the recall problems will have a long-lasting effect on the stock.
Both Gasaway and Forester also added that unlike BP, there are no worries that J&J will have to cut its healthy dividend, which currently yields 3.5%.
"J&J has many strong franchises and a good balance sheet and that helps it to weather the storm," Forester said.
So it may seem strange that investors are not all that upset about the phantom recall issue. But as long as the company's overall sales and profits aren't at risk, J&J stock is likely to remain a Wall Street favorite.
Priceline still flying high and see you on Columbus Day. Quick update on Priceline, which I wrote about in Wednesday's column. Spoke with Mike Olson, an analyst at Piper Jaffray this morning. He still thinks the stock is a good value and cites Europe, despite economic problems there, as a top reason why.
His rationale? Priceline has more exposure there than Oribtz or Expedia (Priceline owns top hotel reservation site Booking.com) and the number of people using online travel services in Europe is much lower than in the United States. So the growth potential is significant.
Anyway, speaking of booking a trip, I'll soon be off to visit the in-laws in Nashville. So no reader comment of the week this week. The Buzz will be back on Monday, October 11. Just in time to celebrate my Italian-American heritage. Capisce?
- The opinions expressed in this commentary are solely those of Paul R. La Monica. Other than Time Warner, the parent of CNNMoney.com, and Abbott Laboratories, La Monica does not own positions in any individual stocks.
Investors are already sifting through the Brexit market rubble for opportunities. Morgan Stanley compiled a list of highly-rated stocks that have limited or no direct exposure to the situation in the U.K. More
In 1998, Ntsiki Biyela won a scholarship to study wine making. Now she's about to launch her own brand. More